Download Free The German Cannabis Protocols Book in PDF and EPUB Free Download. You can read online The German Cannabis Protocols and write the review.

A plant divides the nation: Does cannabis use cause psychosis? Does it damage the brain? Does smoking "weed" make you stupid? Does hemp endanger young people? How great is the risk of addiction and what is "addiction" anyway? Until the decisive vote in the German Federal Council on March 22, 2024, the Cannabis Act was on the brink. Politicians and doctors argued vehemently about these issues. The result of the vote is shown on the book cover. The author has been researching the use of psychoactive substances in society for 20 years. From 2022 to 2024, he accompanied Germany's drug policy paradigm shift in the media. In this book, his most important contributions are compiled for the first time and in revised form. There are also new chapters that provide important basic knowledge. An independent perspective is important: While 100 years ago large parts of the medical profession defended cannabis as a medicinal plant, today many have internalized the false conclusions and demonization of the prohibition policy. Those who are against the legal relaxation of cannabis and other drugs are often exaggerating the risks. And some medical experts are clearly misrepresenting scientific studies. From the content: What is a "drug", what is a "psychoactive substance"? How old is cannabis use in mankind? What do we know about brain development? What does the "cannabis brain" of long-term users look like? What do we make of the age limits that are often set? How does the relaxation of the law influence the frequency of use? What is the risk of psychosis or schizophrenia? A fact check by medical experts. How did the Federal Constitutional Court uphold the ban? Is there really no "right to intoxication"? How did the prohibition policy come about in the 20th century and why do political actors cling to it so stubbornly? What are the risks of prohibition? What would a better drug policy look like? What were the decisive steps leading up to decriminalization on April 1, 2024? What are the benefits and risks of cannabis use? And is the substance addictive? Find out for yourself how much substance there is to the cannabis debate in Germany – and what that means for you.
Advances in medical, biomedical and health services research have reduced the level of uncertainty in clinical practice. Clinical practice guidelines (CPGs) complement this progress by establishing standards of care backed by strong scientific evidence. CPGs are statements that include recommendations intended to optimize patient care. These statements are informed by a systematic review of evidence and an assessment of the benefits and costs of alternative care options. Clinical Practice Guidelines We Can Trust examines the current state of clinical practice guidelines and how they can be improved to enhance healthcare quality and patient outcomes. Clinical practice guidelines now are ubiquitous in our healthcare system. The Guidelines International Network (GIN) database currently lists more than 3,700 guidelines from 39 countries. Developing guidelines presents a number of challenges including lack of transparent methodological practices, difficulty reconciling conflicting guidelines, and conflicts of interest. Clinical Practice Guidelines We Can Trust explores questions surrounding the quality of CPG development processes and the establishment of standards. It proposes eight standards for developing trustworthy clinical practice guidelines emphasizing transparency; management of conflict of interest ; systematic review-guideline development intersection; establishing evidence foundations for and rating strength of guideline recommendations; articulation of recommendations; external review; and updating. Clinical Practice Guidelines We Can Trust shows how clinical practice guidelines can enhance clinician and patient decision-making by translating complex scientific research findings into recommendations for clinical practice that are relevant to the individual patient encounter, instead of implementing a one size fits all approach to patient care. This book contains information directly related to the work of the Agency for Healthcare Research and Quality (AHRQ), as well as various Congressional staff and policymakers. It is a vital resource for medical specialty societies, disease advocacy groups, health professionals, private and international organizations that develop or use clinical practice guidelines, consumers, clinicians, and payers.
The use of cannabis in the late twentieth and this century is an area of medical and moral controversy. Despite its illegality, cannabis is the most widely used drug after alcohol and tobacco among young adults in the USA, Europe and Australia. This book explores the relationship between health policy, public health and the law regarding cannabis use. It assesses the impact of illegality in drug use and relates this to policy analysis in Australia, the UK, the US and other developed societies. It evaluates debates about 'safe use' and 'harm minimisation' approaches, as well as examining the experiences of different prevention, treatment and education policies. Written by two leading drug advisors Cannabis Use and Dependence makes a valuable addition to this important field of research.
Cannabis products are the most widely trafficked drugs worldwide, and it also remains the most widely used drug worldwide. At the same time, production methods have become increasingly sophisticated, resulting in the availability in illicit markets of a wide range of cannabis products. This updated and significantly revised manual has been prepared taking into account both developments in analytical technology and advances in the science of cannabis. It is aimed at the harmonization and establishment of recommended methods of analysis for national drug analysis laboratories. The manual suggests approaches that may assist drug analysts in the selection of methods appropriate to the sample under examination and provide data suitable for the purpose at hand, leaving room also for adaptation to the level of sophistication of different laboratories and the various legal needs.
The cultural, scientific and legislative divide created by vigorous debates over the legalization of medical marijuana is giving way to a new synergy among community stakeholders across the United States. The goal is to improve access to medical marijuana for patients with refractory debilitating neurological disorders, cancer, and chronic pain as an alternative to ineffective pharmacotherapy and potentially addictive pain medications. The ultimate test of our nations resolve to ensure the welfare of our sickest patients is the enactment and implement of effective public health reform in the area of medical marijuana, also known as medical cannabis.This book evolved out of the present need for a definitive volume on the science and public health aspects of medical cannabis to fuel this national narrative. The ethnographic research presented in the concluding chapter was inspired by Professor Miriam W. Boeri and colleagues, at Bentley University in Waltham, MA. They examined views of community stakeholders including medical marijuana dispensary entrepreneurs, health care professionals, and patients in a state that legalized medical marijuana in 2013, yet there continued to be confusion and misunderstandings in the interpretation and implementation of medical marijuana guidelines during the period of policy shifts. Apparent gaps in policy development and implementation signaled the urgency for a comparison study addressing stakeholder views in New York State, where its medical marijuana program has legally dispensed the drug since 2014. The resulting pilot study was carried out in the Division of Health Policy and Management of the City University of New York School of Public Health. The research model incorporated ethnographic and grounded methodologies to detail the views of physicians, pharmacists, educators, patients, and entrepreneur stakeholders; with triangulation of data and application of dominant themes into a socioecological framework model to identify areas of public health policy reform. The findings of this study detail that New York, like other states that recently legalized the dispensation of medical marijuana, faces challenges beyond policy transparency, communication and education explicitly to improve the implementation process for applying and registering medical cannabis dispensaries, referring physicians, and qualified patient recipients.Ken Langone, Chairman of the Board of New York University Langone Health, and Steven Galetta, Chair of Neurology in the School of Medicine, where the authors is senior staff in neuroepidemiology, motivated him to pursue doctoral training in Health Policy and Management. The author has had the good fortune of interacting with thought-provoking medical students, neurology trainees, public health doctoral students, and professors who reinforce the high ethical standards in medical and public health practice and research. However, his patients still educate him in empathy and humanity. The author is grateful to his family, including his spouse Holly and sons Adam and Seth, who serve as his daily compass, encouraging him to take on projects that promote core values of medicine and humanity.
Significant changes have taken place in the policy landscape surrounding cannabis legalization, production, and use. During the past 20 years, 25 states and the District of Columbia have legalized cannabis and/or cannabidiol (a component of cannabis) for medical conditions or retail sales at the state level and 4 states have legalized both the medical and recreational use of cannabis. These landmark changes in policy have impacted cannabis use patterns and perceived levels of risk. However, despite this changing landscape, evidence regarding the short- and long-term health effects of cannabis use remains elusive. While a myriad of studies have examined cannabis use in all its various forms, often these research conclusions are not appropriately synthesized, translated for, or communicated to policy makers, health care providers, state health officials, or other stakeholders who have been charged with influencing and enacting policies, procedures, and laws related to cannabis use. Unlike other controlled substances such as alcohol or tobacco, no accepted standards for safe use or appropriate dose are available to help guide individuals as they make choices regarding the issues of if, when, where, and how to use cannabis safely and, in regard to therapeutic uses, effectively. Shifting public sentiment, conflicting and impeded scientific research, and legislative battles have fueled the debate about what, if any, harms or benefits can be attributed to the use of cannabis or its derivatives, and this lack of aggregated knowledge has broad public health implications. The Health Effects of Cannabis and Cannabinoids provides a comprehensive review of scientific evidence related to the health effects and potential therapeutic benefits of cannabis. This report provides a research agendaâ€"outlining gaps in current knowledge and opportunities for providing additional insight into these issuesâ€"that summarizes and prioritizes pressing research needs.
Now presented in full color, this updated edition of Memory Loss, Alzheimer's Disease, and Dementia is designed as a practical guide for clinicians that delivers the latest treatment approaches and research findings for dementia and related illnesses. Drs. Budson and Solomon — both key leaders in the field — cover the essentials of physical and cognitive examinations and laboratory and imaging studies, giving you the tools you need to consistently make accurate diagnoses in this rapidly growing area. Access in-depth coverage of clinically useful diagnostic tests and the latest treatment approaches. Detailed case studies facilitate the management of both common and uncommon conditions. Comprehensive coverage of hot topics such as chronic traumatic encephalopathy, in addition to new criteria on vascular dementia and vascular cognitive impairment. Includes new National Institute on Aging–Alzheimer's Association and DSM-5 criteria for Alzheimer’s Disease and Mild Cognitive Impairment. Learn how to use new diagnostic tests, such as the amyloid imaging scans florbetapir (Amyvid), flutemetamol (Vizamyl), and florbetaben (Neuraceq), which can display amyloid plaques in the living brains of patients. Updated case studies, many complete with videos illustrating common tests, clinical signs, and diagnostic features, are now incorporated into the main text as clinical vignettes for all major disorders. Brand-new chapters on how to approach the differential diagnosis and on primary progressive aphasia. Expert Consult eBook version included with purchase. This enhanced eBook experience allows you to search all of the text, figures, references, and videos from the book on a variety of devices.
For hundreds of years cannabis has been used as a therapeutic medicine around the world. Cannabis was an accepted medicine during the second half of the 19th century, but its use declined because single agent pain medications were advocated by physicians who demanded standardization of medicines. It was not until 1964 when the chemical structure of THC (delta 9-tetrahydrocannabinol) was elucidated and its pharmacological effects began to be understood. Numerous therapeutic effects of cannabis have been reviewed, but cannabis-based medicines are still an enigma because of legal issues. Many patients could benefit from cannabinoids, terpenoids and flavonoids found in Cannabis sativa L. These patients suffer from medical conditions including chronic pain, chronic inflammatory diseases, neurological disorders, and other debilitating illnesses. As more states are legalizing medical cannabis, prescribers need a reliable source which provides clinical information in a succinct format. This book focuses on the science of cannabis as an antioxidant and anti-inflammatory supplement. It discusses cannabis uses in the human body for bone health/osteoporosis; brain injury and trauma; cancer; diabetes; gastrointestinal conditions; mental health disorders; insomnia; pain; anxiety disorders; depression; migraines; eye disorders; and arthritis and inflammation. There is emphasis on using the whole plant — from root to raw leaves and flowers discussing strains, extraction and analysis, and use of cannabis-infused edibles. Features: Provides an understanding of the botanical and biochemistry behind cannabis as well as its use as a dietary supplement. Discusses endocannabinoid system and cannabinoid receptors. Includes information on antioxidant benefits, pain receptors using cannabinoids, and dosage guidelines. Presents research on cannabis treatment plans, drug-cannabis interactions and dosing issues, cannabis vapes, edibles, creams, and suppositories. Multiple appendices including a glossary of cannabis vocabulary, how to use cannabis products, a patient guide and recipes as well as information on cannabis for pets.
Although primarily used today as one of the most prevalent illicit leisure drugs, the use of Cannabis sativa L., commonly referred to as marijuana, for medicinal purposes has been reported for more than 5000 years. Marijuana use has been shown to create numerous health problems, and, consequently, the expanding use beyond medical purposes into recreational use (abuse) resulted in control of the drug through international treaties. Much research has been carried out over the past few decades following the identification of the chemical structure of THC in 1964. The purpose of Marijuana and the Cannabinoids is to present in a single volume the comprehensive knowledge and experience of renowned researchers and scientists. Each chapter is written independently by an expert in his/her field of endeavor, ranging from the botany, the constituents, the chemistry and pharmacokinetics, the effects and consequences of illicit use on the human body, to the therapeutic potential of the cannabinoids.